Share: Facebook Twitter LinkedIn
Activity Provided By:

Vindico

Keeping an Eye Out: Emerging Trends in the Management of Metastatic Uveal Melanoma

Access Activity

Overview / Abstract:

Target Audience
The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with uveal melanoma.

Program Overview
Uveal melanoma is the most common ocular cancer, typically affecting older patients, particularly men. It is associated with a high mortality rate, especially after metastases. Individuals with fair skin and eyes are more susceptible to the disease due to a lower amount of melanin. Diagnosing uveal melanoma is challenging, as only approximately 30% of patients experience symptoms, such as secondary glaucoma and changes in iris color and pupil shape, thus misdiagnosis is common. The current standard of care for uveal melanoma includes enucleation, globe-preserving therapies, or radiotherapy, but the rates of metastases remain high. Ongoing research has yielded a greater understanding of the disease mechanisms, which has led to advances in biomarkers and therapies. However, given the novelty of these studies, as well as the disease mechanisms that differ from other skin cancers, oncology providers need timely education on these topics to remain current. In this educational activity, expert faculty review the most recent data regarding the molecular basis of uveal melanoma and the clinical data supporting the use of new and emerging therapies. They also explore the potential role of novel therapies in the current treatment algorithm for uveal melanoma.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Explain the latest understanding regarding the molecular basis of uveal melanoma.
Critically appraise the latest data regarding the safety and efficacy of new/emerging treatment options for patients with advanced uveal melanoma.
Outline how new or emerging options may fit into existing treatment algorithms for patients with uveal melanoma.

Expiration

Dec 30, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

0.75

Accreditation

ACCME

Presenters / Authors / Faculty

Alexander N. Shoushtari, MD
Prof. Dr. med. Jessica C. Hassel

Sponsors / Supporters / Grant Providers

Immunocore

Keywords / Search Terms

Relias LLC Relias, Free CME, Uveal Melanoma Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map